Last $62.02 USD
Change Today +0.77 / 1.26%
Volume 344.9K
CYBX On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

cyberonics inc (CYBX) Snapshot

Open
$60.98
Previous Close
$61.25
Day High
$62.22
Day Low
$60.83
52 Week High
02/14/14 - $73.52
52 Week Low
04/26/13 - $42.49
Market Cap
1.7B
Average Volume 10 Days
290.2K
EPS TTM
$1.95
Shares Outstanding
26.8M
EX-Date
--
P/E TM
31.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for CYBERONICS INC (CYBX)

cyberonics inc (CYBX) Related Bloomberg News

View More Bloomberg News

cyberonics inc (CYBX) Related Businessweek News

No Related Businessweek News Found

cyberonics inc (CYBX) Details

Cyberonics, Inc., together with its subsidiaries, engages in the design, development, marketing, and sale of implantable medical devices to hospitals and ambulatory surgery centers. The company offers vagus nerve stimulation (VNS) therapy system that provides neuromodulation therapy for the treatment of refractory epilepsy and treatment-resistant depression. It also engages in investigating the use of VNS and other neuromodulation therapy for other indications, including chronic heart failure, and developing non-implantable device solutions for the management of epilepsy. The company sells its products directly, as well as through independent distributors in Europe, Canada, Mexico, Australia, parts of Central and South America, the Middle East, China, Japan, and other parts of Asia. Cyberonics, Inc. was founded in 1987 and is headquartered in Houston, Texas.

581 Employees
Last Reported Date: 06/19/13
Founded in 1987

cyberonics inc (CYBX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $562.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $324.1K
Chief Administrative Officer, Senior Vice Pre...
Total Annual Compensation: $307.5K
Senior Vice President of Research & Developme...
Total Annual Compensation: $297.5K
Vice President of Emerging Therapies
Total Annual Compensation: $100.4K
Compensation as of Fiscal Year 2013.

cyberonics inc (CYBX) Key Developments

Cyberonics Inc. Announces CE Mark Approval Of The AspireSR Generator for VNS Therapy

Cyberonics Inc. announced the CE Mark (Conformité Européenne) approval in Europe for the AspireSR generator, the novel sixth-generation VNS Therapy generator. The AspireSR generator provides the well-established benefits of VNS Therapy, coupled with a new feature -- Automatic Stimulation in response to detection of a seizure. Proprietary technology enables the AspireSR generator to analyze relative heart rate changes to detect and respond to seizures. This technology is based on a growing body of evidence that seizures are often accompanied by an increase in heart rate (ictal tachycardia). With the Automatic Stimulation feature, the AspireSR generator better aligns stimulation with the clinical onset of a seizure. Currently, patients experiencing VNS Therapy can use a hand-held magnet to activate stimulation manually when they anticipate the onset of a seizure. This on-demand stimulation has been shown to stop or shorten a seizure, reduce seizure severity, and improve or shorten the postictal (post-seizure) recovery period. The Automatic Stimulation feature of the AspireSR generator may benefit patients who experience seizures accompanied by ictal tachycardia and are unable to perform on-demand stimulation with the hand-held magnet, do not have a magnet available when needed, or experience a seizure while sleeping. Results of the E-36 clinical study, which evaluated the performance and safety of the AspireSR generator, were presented at the American Epilepsy Society meeting in December 2013. The study met its primary performance endpoint, and the safety profile for the AspireSR generator is consistent with currently available VNS Therapy systems.

Cyberonics Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended January 24, 2014; Revises Earnings Guidance for the Fiscal Full Year 2014

Cyberonics Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended January 24, 2014. For the quarter, the company's net sales were $68,191,414 against $62,700,033 a year ago. Income from operations was $21,102,050 against $20,441,558 a year ago. Income before income taxes was $21,106,214 against $20,331,929 a year ago. Net income was $13,899,863 or $0.51 diluted per share against $13,183,494 or $0.47 diluted per share a year ago. Adjusted non-GAAP net income was $13,899,863 or $0.51 diluted per share against $13,183,494 or $0.47 diluted per share a year ago. Adjusted non-GAAP income from operations was $21,102,050 against $20,441,558 a year ago. Adjusted EBITDA was $25,188,250 against $23,826,107 a year ago. For the nine months, the company's net sales were $207,164,890 against $185,976,849 a year ago. Income from operations was $56,593,730 against $57,882,878 a year ago. Income before income taxes was $56,515,344 against $54,915,005 a year ago. Net income was $36,462,251 or $1.32 diluted per share against $34,825,431 or $1.24 diluted per share a year ago. Net cash provided by operating activities was $37,748,283 against $55,705,285 a year ago. Intangible asset purchases were $3,789,000 against $2,500,000 a year ago. Purchases of property, plant and equipment was $12,960,959 against $6,515,509 a year ago. Adjusted non-GAAP net income was $41,238,326 or $1.50 diluted per share against $35,972,458 or $1.28 diluted per share a year ago. Adjusted non-GAAP income from operations was $64,036,577 against $57,882,878 a year ago. Adjusted EBITDA was $76,578,774 against $70,433,314 a year ago. The company maintains guidance for the net sales to be in the range of $281 million to $285 million. Adjusted non-GAAP income from operations is expected to be in the range of $86 million to $88 million. The company is increasing its fiscal 2014 guidance for the adjusted non-GAAP net income for fiscal 2014 is expected to be in the range from $55 million to $57 million. Previously, that was at $54 million to $56 million. Adjusted non-GAAP diluted earnings per share (EPS) is expected be in the range from $2.00 to $2.05 from a previous guidance of $1.97 to $2.03. Guidance for income from operations, net income and diluted earnings per share (EPS) was adjusted by $7.4 million, $4.8 million (net of tax) and $0.17 per share, respectively, for the litigation settlement recorded in the first quarter of fiscal 2014.

Cyberonics Inc. Presents at RBC Capital Markets 2014 Global Healthcare Conference, Feb-25-2014

Cyberonics Inc. Presents at RBC Capital Markets 2014 Global Healthcare Conference, Feb-25-2014 . Venue: New York Palace Hotel, New York, New York, United States. Speakers: Gregory H. Browne, Chief Financial Officer, Principal Accounting Officer and Senior Vice President of Finance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYBX:US $62.02 USD +0.77

CYBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArthroCare Corp $48.61 USD +0.11
ICU Medical Inc $55.98 USD -0.40
Thoratec Corp $33.60 USD -0.32
Tornier NV $18.38 USD +0.14
Wright Medical Group Inc $28.42 USD +0.03
View Industry Companies
 

Industry Analysis

CYBX

Industry Average

Valuation CYBX Industry Range
Price/Earnings 35.7x
Price/Sales 6.1x
Price/Book 6.9x
Price/Cash Flow 34.7x
TEV/Sales 5.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYBERONICS INC, please visit www.cyberonics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.